Perseus Proteomics Inc.
Summary of Q2 Q&A Including Clinical Results and Partnership Trends for PPMX-T003
The company positions expansion of collaborative research agreements as a growth strategy. Master cell bank manufacturing for PPMX-T004 is scheduled to start in January 2027. Of the planned fundraising under the 29th share acquisition rights of approximately 930 million yen, about 700 million yen has been raised. The ASH presentation will inform licensing/out-licensing decisions, but any deal is up to the partner company. Approval of PTX3 is expected to have a minor impact on results, but details remain undisclosed.
Key Figures
- Of the approximately 930 million yen fundraising plan, about 700 million yen was raised and completed in June
- PPMX-T004 development costs of 150 million yen are expected to be incurred from autumn 2026 onward and will be expended going forward
- PPMX-T003 is scheduled for presentation at ASH (licensing decision depends on the partner company)
AI要約
Business and Partnership Progress
As part of its growth strategy, the company promotes collaboration with external partners, expanding ties including a collaborative research agreement with Kyorin Pharmaceutical and previous collaborations with Asuka Pharmaceutical and Eurus Therapeutics. Going forward, the company aims to maximize business value through collaboration with external partners built on its drug discovery platform.
Fundraising and R&D Progress
Fundraising through the 29th issuance of share acquisition rights planned for approximately 930 million yen has raised about 700 million yen. Master cell bank manufacturing for PPMX-T004 is scheduled to begin in January 2027. Clinical study results will be subject to the licensee's decision, and the ASH presentation will serve as supplemental clinical data. Timing of future fundraising is currently unknown.
Perseus Proteomics Inc.
Company overview · Stock price · Financial data · All IR